Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 13;21(1):12.
doi: 10.1186/s12881-020-0947-z.

Assessment of cellular cobalamin metabolism in Gaucher disease

Affiliations

Assessment of cellular cobalamin metabolism in Gaucher disease

Suelen Porto Basgalupp et al. BMC Med Genet. .

Abstract

Background: Gaucher disease (GD) is a lysosomal disorder caused by biallelic pathogenic mutations in the GBA1 gene that encodes beta-glucosidase (GCase), and more rarely, by a deficiency in the GCase activator, saposin C. Clinically, GD manifests with heterogeneous multiorgan involvement mainly affecting hematological, hepatic and neurological axes. This disorder is divided into three types, based on the absence (type I) or presence and severity (types II and III) of involvement of the central nervous system. At the cellular level, deficiency of GBA1 disturbs lysosomal storage with buildup of glucocerebroside. The consequences of disturbed lysosomal metabolism on biochemical pathways that require lysosomal processing are unknown. Abnormal systemic markers of cobalamin (Cbl, B12) metabolism have been reported in patients with GD, suggesting impairments in lysosomal handling of Cbl or in its downstream utilization events.

Methods: Cultured skin fibroblasts from control humans (n = 3), from patients with GD types I (n = 1), II (n = 1) and III (n = 1) and an asymptomatic carrier of GD were examined for their GCase enzymatic activity and lysosomal compartment intactness. Control human and GD fibroblasts were cultured in growth medium with and without 500 nM hydroxocobalamin supplementation. Cellular cobalamin status was examined via determination of metabolomic markers in cell lysate (intracellular) and conditioned culture medium (extracellular). The presence of transcobalamin (TC) in whole cell lysates was examined by Western blot.

Results: Cultured skin fibroblasts from GD patients exhibited reduced GCase activity compared to healthy individuals and an asymptomatic carrier of GD, demonstrating a preserved disease phenotype in this cell type. The concentrations of total homocysteine (tHcy), methylmalonic acid (MMA), cysteine (Cys) and methionine (Met) in GD cells were comparable to control levels, except in one patient with GD III. The response of these metabolomic markers to supplementation with hydroxocobalamin (HOCbl) yielded variable results. The content of transcobalamin in whole cell lysates was comparable in control human and GD patients.

Conclusions: Our results indicate that cobalamin transport and cellular processing pathways are overall protected from lysosomal storage damage in GD fibroblasts. Extending these studies to hepatocytes, macrophages and plasma will shed light on cell- and compartment-specific vitamin B12 metabolism in Gaucher disease.

Keywords: Beta-glucosidase; Cobalamin; Gaucher disease; Homocysteine; Methylmalonic acid; Transcobalamin; Vitamin B12.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
α- and β-glucosidase activity in healthy human controls, Gaucher disease patients and an asymptomatic carrier of GD. a Gaucher patients (n = 3) had no detectable activity of β-glucosidase (nmol/mLxh), whereas the asymptomatic carrier of GD (n = 1) exhibited β-glucosidase activity comparable to those of human controls (n = 3); b All examined subjects presented comparable α-glucosidase activity (nmol/mLxh), suggesting preserved activity of lysosomal components not associated with the GBA1 mutation. Legend: without HOCbl – culture medium without hydroxocobalamin; with HOCbl – culture medium with hydroxocobalamin, GD – Gaucher disease, RecNciI/− − asymptomatic carrier of GD
Fig. 2
Fig. 2
Content of transcobalamin in healthy human controls, Gaucher disease patients and an asymptomatic carrier of GD. a Whole cell lysates (30 μg) of human control and GD fibroblasts were examined for intracellular content of transcobalamin, with and without HOCbl supplementation. Under our experimental conditions, no differences were identified between control and GD cells, suggesting normal expression of transport protein transcobalamin. Left panel: Western blot results obtained by probing whole cell lysates with anti-TC (rabbit anti-human, dilution 1:500) and secondary goat anti-rabbit IgG-HRP (1:1000) antibody. Right panels: Ponceau staining of nitrocellulose membrane after semi-dry blot transfer as protein loading control. b Semi-quantitative analysis of TC content shown in panel (a) shows slightly reduced TC content in GD cells compared to healthy human controls, albeit without statistical significance. Values shown are mean normalized areas plus minus standard error of the mean

Similar articles

References

    1. Beutler E, Grabowski GA, et al. Gaucher disease. In: Scriver CBA, Beaudet AL, et al., editors. The metabolic & molecular bases of inherited disease. New York: McGraw-Hill; 2001. pp. 3635–3668.
    1. Vaccaro AM, Mota M, Tatti M, Scarpa S, Masuelli L, Bhat M, et al. Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet. 2010;19:2987–2997. doi: 10.1093/hmg/ddq204. - DOI - PubMed
    1. Grabowski GA, Petsko GA, Kolodny EH, et al. Gaucher Disease. In: Valle D, Beaudet AL, et al., editors. OMMBID – the Online Metabolic & Molecular Bases of inherited disease. New York: McGraw-Hill; 2013.
    1. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441. doi: 10.3390/ijms18020441. - DOI - PMC - PubMed
    1. Roshan LT, Sidransky E. The Spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017;5(1):10. doi: 10.3390/diseases5010010. - DOI - PMC - PubMed

Publication types